2023 APASL Trainee Workshop Winners

   Shang-Chin Huang

Dr. Shang-Chin Huang is an attending physician in gastroenterology and hepatology at the Hepatitis Research Center and Bei-Hu Branch of National Taiwan University Hospital (NTUH), Taipei, Taiwan. He is also a PhD student at the National Taiwan University College of Medicine, where his research focuses on the interaction between hepatitis B virus (HBV), fatty liver disease, and systemic metabolic dysfunction. Dr. Huang has recently been recognized with the Young Investigator Awards (YIA) at the 2022 Asian Pacific Association for the Study of the Liver (APASL) STC on HCC, the 2022 Taiwan Digestive Disease Week (TDDW), and the 2023 APASL Annual Meeting.

Selected Publications (first author)

1. Hepatitis B Reactivation: Diagnosis and Management. 
SC Huang, HC Yang, JH Kao. Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):565-578.

2. Direct Comparison of Biopsy Techniques for Hepatic Malignancies. 
SC Huang, JD Liang, SJ Hsu, TC Hong, HC Yang, JH Kao. Clin Mol Hepatol. 2021 Apr;27(2):305-312.

3. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. 
SC Huang, HJ Su, JH Kao, TC Tzeng, HC Yang, TH Su, PJ Chen, CJ Liu Gut and Liver. 2021 May 15;15(3):451-458.

4. Clinical Manifestations and Outcomes of Patients with Scirrhous Hepatocellular Carcinoma. 
SC Huang, SH Liao, TH Su, YM Jeng, JH Kao. Hepatol Int. 2021 Apr;15(2):472-481.

5. Management of Hepatitis B in Persons Who Inject Drugs (PWID).
SC Huang, JH Kao. Current Hepatology Reports. 2021 Oct 19; 20:158–165.

6. Hepatic steatosis and fibrosis in chronic hepatitis B: the chicken-and-egg conundrum.
SC Huang, JH Kao. Alimentary Pharmacology & Therapeutics. 2022 Jan;55(1):143-144.

7. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents.
SC Huang, PN Cheng, CH Liu, HC Yang, TH Su, TC Tseng, PJ Chen, JH Kao, CJ Liu. Journal of the Formosan Medical Association. 2022 May;121(5):920-929.

8. Strategies for hepatitis C virus treatment failure.
SC Huang, JH Kao. Journal of the Formosan Medical Association. 2022 May;121(5):876-878. 

9. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. 
SC Huang, JH Kao. J Formos Med Assoc. 2022 Nov;121(11):2148-2151.

10. Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B
SC Huang, JH Kao. Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.  

11. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
SC Huang, CJ Liu Clin Mol Hepatol. 2023 Apr;29(2):320-331.

12. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B
SC Huang, TH Su, TC Tseng, CL Chen, SJ Hsu, SH Liao, CM Hong, CH Liu, TY Lan, HC Yang, CJ Liu, PJ Chen, JH Kao Hepatol Int. 2023 (accepted)

   Sih-Han Liao

Dr. Sih-Han Liao attained her doctoral degree from Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan in 2022. Her main research area includes epidemiology and clinical research of hepatocellular carcinoma, preventive medicine, public health, economic analysis, and biostatistics. Her work focuses on the impact and cost-effectiveness analysis of multiple interventions on the prevention of hepatocellular carcinoma at population level using newly developed statistical method. It can provide substantial evidence for policy makers to allocate resources for the prevention of hepatocellular carcinoma. On the other hand, I conduct research with the database of electronic medical record from National Taiwan University Hospital to investigate the clinical characteristics and outcomes of hepatocellular carcinoma among different histological subtypes and etiologies (viral vs non-viral). Now, as a clinical hepatologist, Dr. Sih-Han Liao works at the National Taiwan University Cancer Center (NTUCC), Taipei, Taiwan. Her main clinical role is providing care for patients with chronic viral hepatitis and hepatocellular carcinoma both in the inpatient and outpatient setting. One specific highlight is that she along with Professor Yao-Ming Wu (surgeon), Professor Chiun Hsu (oncologist), Dr. Zhong-Zhe Lin (oncologist), Dr. Ying-Chun Shen (oncologist), and Dr. Kao-Lang Liu (interventional radiologist) partner together to manage a majority of the liver cancer patients at NTUCC. This includes active participation in the weekly tumor board conference of the multidisciplinary team to discuss the treatment plan and conduct the relevant research. 

Selected Publications

1.Pre-operative gamma-glutamyl transferase levels predict outcomes in hepatitis B-related hepatocellular carcinoma after curative resection.
Tung-Hung Su, Shang-Chin Huang, Chi-Ling Chen,Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Tai-Chung Tseng, Chen-Hua Liu, Hung-Chih Yang,
Yao-Ming Wu, Chun-Jen Liu, Pei-Jer Chen,Jia-Horng Kao
J Formos Med Assoc. 2023 May Accepted

2.Optimizing Survival Benefit by Surgical Resectionby the Seven-Eleven Criteria in Barcelona Clinic Liver Cancer Stage A/B Hepatocellular Carcinomabeyond the Milan Criteria
Chian-Tzu Huang,Yu-Long Chu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng,Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Liver Cancer (2023): 1-11.

3.Evaluating correlates of protection for mix-match vaccine against COVID-19 VOCs with potential of evading immunity.
Sih-Han Liao, Wei-Jung Chang, Chen-Yang Hsu, Amy Ming-Fang Yen, Ting-Yu Lin, Sam Li-Sheng Chen,Tony Hsiu-Hsi Chen Vaccine. 2022 Oct 17;40(47):6864-6872. doi: 10.1016/j.vaccine.2022.10.011.

4.Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. 
SH Liao, CC Hung, CN Chen, JY Yen, CY Hsu, Amy MF Yen, CL Chen
J Formos Med Assoc. 2021 Jun;120 Suppl 1:S77-S85. doi: 10.1016/j.jfma.2021.04.026. Epub 2021 May 4.

5.Effectiveness of non-pharmaceutical interventions and vaccine for containing the spread of COVID-19: Three illustrations before and after vaccination periods.
TY Lin, SH Liao, CC Lai, E Paci, SY Chuang J Formos Med Assoc. 2021 Jun;120 Suppl 1:S46-S56. doi: 10.1016/j.jfma.2021.05.015. Epub 2021 May 25.

6.Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan.
SH Liao, CL Chen, CY Hsu, KL Chien, JH Kao, PJ Chen, Tony HH Chen, CH Chen J Hepatol. 2021 Jul;75(1):132-141. doi: 10.1016/j.jhep.2021.02.029. Epub 2021 Mar 6.

7.Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. 
SC Huang, SH Liao, TH Su, YM Jeng, JH Kao Hepatol Int. 2021 Feb 5. doi: 10.1007/s12072-021-10146-1. Online ahead of print.

8.A woman from Vietnam complained of chronic diarrhea: A case report and literature review. 
SY Wang, SH Liao AIDM. 09 October 2020. https://doi.org/10.1002/aid2.13249.

9.Hepatobiliary and Pancreatic: Biliary hamartoma manifests as liver cysts.
HH Lin, SH Liao, YL Huang, KL Liu, JH Kao J Gastroenterol Hepatol. 2020 Jan;35(1):11. doi: 10.1111/jgh.14821. Epub 2019 Nov 11.

10.NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. 
Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Adhoute X, Bourlière M, Kao JH. J Gastroenterol Hepatol. 2019 Dec;34(12):2179-2186.doi: 10.1111/jgh.14705. Epub 2019 Jun 18.

11.Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma. 
Liao SH, Su TH, JengYM, Liang PC, Chen DS, Chen CH, Kao JH.
Hepatology. 2019 Jan;69(1):209-221. doi: 10.1002/hep.30162.

12.An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review. 
Liao SH, Chen YK, Yu SC, Wu MS, Wang HP, Tseng PH. 
SAGE Open Med Case Rep. 2017 May 26;5:2050313X17709190. doi: 10.1177/2050313X17709190. eCollection 2017.

13.Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy. 
Lin KY, Liao SH, Liu WC, Cheng A, Lin SW, Chang SY, Tsai MS, Kuo CH, Wu MR, Wang HP, Hung CC, Chang SC. PLoS One. 2015 Sep 11;10(9):e0137660. doi: 10.1371/journal.pone. 0137660. eCollection 2015.

   Asako Nogami

Dr. Asako Nogami is an assistant professor working at Yokohama City University Graduate School of Medicine, Yokohama, Japan. She graduated from the Department of Medicine, Sapporo Medical University in 2012 and received a Ph.D. from Yokohama City University Graduate School of Medicine in 2022.  As a hepatologist, she has great interest in evaluating chronic liver disease (especially NAFLD) through noninvasive tests. She is actively involved in collaborative research with several institutions and welcomes new collaborations with other institutions as well.

Selected Publications

Original Article
1.Nogami A, et al. Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study. J Gastroenterol Hepatol. 2023. 
2.Nogami A, et al. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. Sci Rep.2022. 

Review Article 
1.Nogami A, et al. Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future. Clin Mol Hepatol. 2023.
 
Case Report 
1.Nogami A, et al. Mortality associated with the development of acute liver failure after a single dose of nivolumab. Clin J Gastroenterol. 2023.